Loss of SPATA7 function causes the pathogenesis of Leber congenital amaurosis and retinitis pigmentosa. Spata7 knockout mice mimic human SPATA7-related retinal disease with apparent photoreceptor degeneration observed as early as postnatal day 15 (P15). To test the efficacy of adeno-associated virus (AAV)-mediated gene therapy for rescue of photoreceptor survival and function in Spata7 mutant mice, we employed the AAV8(Y733F) vector carrying hGRK1-driven full-length FLAG-tagged Spata7 cDNA to target both rod and cone photoreceptors. Following subretinal injection of this vector, FLAG-tagged SPATA7 was found to colocalize with endogenous SPATA7 in wild-type mice. In Spata7 mutant mice initially treated at P15, we observed improvement of photoresponse, photoreceptor ultrastructure and significant alleviation of photoreceptor degeneration. Furthermore, we performed treatments at P28 and P56 and found that all treatments (P15-P56) can ameliorate rod and cone loss in the long term (1 year); however, none efficiently protect photoreceptors from degeneration by 86 weeks of age as only a small amount of treated photoreceptors can survive to this time. This study demonstrates long-term improvement of photoreceptor function by AAV8 (Y733F)-introduced Spata7 expression in a mouse model as potential treatment of the human disease, but also suggests that treated mutant photoreceptors still undergo progressive degeneration.
INTRODUCTION
Leber congenital amaurosis (LCA) is clinically characterized by severe and early visual loss, sensory nystagmus, amaurotic pupils, fundus changes and minimal or absent electrical signals on electroretinogram (ERG). 1 The pathogenesis is mainly due to rodcone dystrophy. 2, 3 LCA is an important cause of blindness, accounting for about 20% of children in schools for the blind and affects 1-2 per 80 000 live births. 2, 4 Retinitis pigmentosa (RP) is a relatively common retinal disease, affecting 1:4000 people around the world. 5 Compared with LCA, RP has a delayed onset phenotype for retinal dystrophy and then shows progressive degeneration of rod and cone photoreceptors; however, severe blindness eventually develops. 5 LCA and RP are genetically highly heterogeneous and share important clinical features as well as disease-causing genes. 6, 7 Deleterious mutations in SPATA7 (spermatogenesis-associated protein 7) lead to LCA and RP 7 and these phenotypes have been replicated in the Middle East, East and South Asia, and Europe, 3, 8, 9 indicating the prevalence across different populations. Although the pathogenic contributions of different mutations in SPATA7 are variable, SPATA7 mutations consistently cause rod-cone dystrophy as judged by reduced rodand cone-driven ERGs. 8, 9 A Spata7 mutant mouse model was generated to understand the pathogenesis of SPATA7 retinopathy. 10 As expected, Spata7 mutant mice mimic SPATA7-related LCA and RP disease phenotypes. From postnatal day 15 (P15), a progressive reduction of photoresponse is observed. Further investigation found significant rhodopsin mislocalization, photoreceptor degeneration and disorganization of photoreceptor outer segments (OS) in Spata7 mutant retinas. Importantly, the observed pathologies are progressive: at 1 month of age, about half of the photoreceptor cells still survive and are functional as assayed by ERG and even at 6 months, 30-40% of photoreceptor cells remain compared with wild type. 10 These findings indicate that the Spata7 mouse model is an ideal candidate for gene therapy as there is a wide time window in which photoreceptors are present and functional.
Adeno-associated virus (AAV) has been widely accepted as an efficient vector to deliver functional genes into mutant retinas to rescue disease phenotypes in animal disease models and human patients. [11] [12] [13] Recent modifications in AAV serotypes as well as utilizing a cell-type-specific promoter have enabled our AAV vector to achieve high-transduction efficiency, early onset of expression, cell transduction specificity, and stable and long-term expression. [14] [15] [16] [17] [18] [19] [20] Among numerous AAV serotypes, a tyrosinecapsid mutant AAV vector, AAV8(Y733F), displays higher transduction efficiency and more rapid onset of expression in photoreceptor cells 15 and has been successfully used to treat Aipl1 and rd10 mice, both showing early degeneration of photoreceptor cells in the absence of treatment. 18, 21 Furthermore, the human rhodopsin kinase (hGRK1) promoter is able to drive transgene expression in both rod and cone photoreceptors following subretinal delivery of an AAV vector. 16, 22 Recently, the combination of AAV8(Y733F) and the hGRK1 promoter was applied to properly drive RetGC1 expression in RetGC1/RetGC2 compound mutant mice and restore rod and cone function. 17 In Spata7 mutant mice, degeneration of photoreceptor cells is observed beginning at P15 but without morphological defects found in any other retinal cell types, 10 suggesting that this model is amenable to gene therapy using a combination of AAV8(Y733F) and the hGRK1 promoter.
In this study, by subretinal delivery of AAV8(Y733F)-hGRK1-Spata7, we performed treatments of Spata7 mutant mice with different vector dosages and different injection time points (P15, P28 and P56). We found that AAV-mediated Spata7 expression significantly improves photoreceptor function as assessed by ERGs, prevents rhodopsin mislocalization, slows rod and cone photoreceptor degeneration, and preserves photoreceptor ultrastructure in the long term, about one year. Our findings demonstrate significant therapeutic efficacy by AAV8(Y733F)mediated Spata7 expression in our retinal disease mouse model although we also found that no treatment tested can efficiently protect photoreceptors from degeneration in mice at 86 weeks of age. This work opens up the possibility for treatment in humans with retinal pathologies associated with SPATA7 mutations.
RESULTS

AAV-mediated Spata7 expression in photoreceptor cells
In order to express exogenous Spata7 in the eye, an AAV8 vector delivering green fluorescent protein (GFP) driven with the hGRK1 promoter (AAV8(Y733F)-hGRK1-GFP (AAV8-GFP)) was generated and injected in P15 wild-type mouse retinas. GFP was apparent at 3 days post injection and expression increased by 7 days in a large fraction of the injected retina (data not shown). These observations are consistent with previously reported results 15, 18 and confirm that the combination of AAV8(Y733F) and hGRK1 can efficiently drive gene expression in the mouse retina.
To test if exogenous Spata7 can be efficiently expressed following subretinal injection, AAV8(Y733F)-hGRK1-3 × FLAG-Spata7 (AAV8-Spata7) was generated ( Figure 1a ). AAV8-Spata7 was injected into P15 Spata7 mutant and wild-type retinas, and as expected, 3 × FLAG-Spata7 is detected by RT-PCR in injected retinas at 7 days post injection (data not shown). Western blots show an expected band of~69 kDa for 3xFLAG-SPATA7 in both injected wild type and Spata7 mutant retinal samples ( Figure 1b) . A smaller endogenous SPATA7 band of~66 kDa is detected only in wild-type retinas. This demonstrates that AAV8-Spata7 is able to direct SPATA7 protein expression in the eye. To determine whether vector delivered SPATA7 has the same protein location in the photoreceptor cells to the endogenous, immunofluorescence staining was performed using sections from paired uninjected and injected wild-type eyes sacrificed at 42 days post injection ( Figure 1c ). FLAG expression is observed in AAV8-Spata7 injected retinas and is also found to colocalize with anti-SPATA7 signals. In addition, AAV8-Spata7 expression in Spata7 mutant retinas was examined by immunofluorescence staining and showed correct subcellular localization in photoreceptor cells (Supplementary Figure S1 ). In addition, large areas of Spata7 expression in the retina can be achieved, covering both temporal and nasal hemispheres (Supplementary Figure S1a ) or about half of the nasal hemishpere (Supplementary Figure S1d) . The distributions of 3xFLAG-SPATA7 expression observed in treated retinas are consistent with the site of injection (i.e., nasal or ventral). These findings demonstrate that the combination of AAV8(Y733F) and hGRK1 efficiently drives Spata7 expression with the proper subcellular location in photoreceptors.
We also observed that AAV8-Spata7 expression is higher than physiological levels. As shown in western blots (Figure 1b ), 3xFLAG-SPATA7 is overexpressed compared with endogenous SPATA7. This is further reflected by the mislocalization of 3xFLAG-SPATA7 to photoreceptor inner segments as detected by immunofluorescence staining (Supplementary Figure S1 ).
AAV-mediated Spata7 expression improves photoreceptor survival, function and ultrastructure in P15-treated Spata7 mutant mice We next tested whether AAV8-Spata7 could rescue photoresponses in Spata7 mutant mice. To this end, we performed subretinal injections of AAV8-Spata7 in P15 Spata7 mutant mice and wild-type littermates (as controls to evaluate potential AAV toxicity). Our recently published results showed that photoreceptor degeneration is first detected in P15 Spata7 mutant mice. Degeneration is progressive and about 50% of photoreceptor cells remain and are functional at P30 as assayed by ERG. 10 Therefore, treatments at this time can be used to determine whether photoresponses in Spata7 mutant mice could be rescued by AAVmediated gene replacement therapy.
Significantly improved ERGs are observed at all four time points tested (8, 16, 24 and 52 weeks of age or 6, 14, 22 and 50 weeks post injection) in Spata7 mutant eyes treated with 10 9 vector genome containing particles (significance determined by ANOVA analysis, Figures 2a and b ). Functional improvement is consistently observed for at least 1 year post injection. We also tested if lower dosages of AAV8-Spata7 (10 8 and 10 7 vector genome particles per microliter (vg μl − 1 )) could provide good therapeutic effects. For these two lower-dosage treatments, ERGs were measured at 14 and 22 weeks post injection and no significantly increased a-and b-wave amplitudes were observed in treated eyes (data not shown). Furthermore, treatment with a dosage of 10 9 vg μl − 1 showed significantly better improvement of ERG a and b waves than treatments with dosages of 10 8 or 10 7 vg μl − 1 at 22 weeks post injection (Figures 2c and d) . The improved ERGs demonstrate the therapeutic effect of AAV8-Spata7 and also exclude the concern of transgenic toxicity, which can also be reflected from our wild-type control group. P15-injected wild-type mice with 10 9 vg μl − 1 of AAV8-Spata7 did not show significantly decreased ERGs in injected eyes compared with uninjected contralateral controls (Supplementary Figure S2a and b). Treatments with 10 9 particles were selected for all further experiments to evaluate therapeutic effects.
In addition to a marked decrease in photoresponse, Spata7 knockout mice also exhibit distinct rhodopsin mislocalization that is likely to have a key role in photoreceptor degeneration. 10 Therefore, it is essential to determine whether AAV8-Spata7 gene replacement therapy can prevent rhodopsin mislocalization. At 6 weeks post injection, we observed significant association between AAV8-Spata7 expression and a correspondingly reduced rhodopsin mislocalization (data not shown). At 22 weeks post injection, we further performed a detailed examination in five Figure S1e) . In contrast, severe rhodopsin mislocalization is not reduced in retinas treated with 10 7 or 10 8 vg μl − 1 , in which very low or sporadic AAV8-Spata7 expression is observed (data not shown). These results suggest that the observed reduction of rhodopsin mislocalization is attributable to high AAV8-Spata7 expression and is closely associated with improved photoresponse.
AAV8-Spata7-mediated therapeutic effect also results in increased photoreceptor survival as measured by the number of photoreceptor nuclei in the outer nuclear layer (ONL). The five treated mice discussed above, where both improved photoresponse and reduced rhodopsin mislocalization were observed, were used to evaluate photoreceptor survival by comparing the ONL from treated and untreated retinas. To this end, a defined region of the ONL close to optic nerve on both the temporal and nasal sides of each horizontal section for each treated and contralateral control eye was quantified. The number of nuclei in each defined ONL region was counted three times and averaged. We found that regions with substantial AAV8-Spata7 expression (marked by an asterisk, Figure 3d ) have significantly more photoreceptor cells than contralateral untreated regions. In particular, as each mouse consistently displayed AAV8-Spata7 expression in the nasal hemisphere of treated eyes, we compared treated and untreated nasal hemispheres. Significantly (P = 0.012), more photoreceptor cells were observed in AAV8-Spata7 treated areas (Figure 3d ). These data strongly suggest that AAV8-Spata7 gene replacement therapy alleviates rhodopsin mislocalization and photoreceptor degeneration in Spata7 mutant mice.
Our previous results show that loss of Spata7 function causes shortened and disorganized photoreceptor outer segments in addition to rhodopsin mislocalization and photoreceptor degeneration. 10 As alleviated photoreceptor degeneration and rhodopsin mislocalization are observed, we expected that AAV8-Spata7 expression should also improve OS structure. Therefore, transmission electron microscopy (TEM) was performed to evaluate the effect of AAV8-Spata7 treatment on photoreceptor ultrastructure at 22 weeks post injection. Consistent with our previous results, photoreceptors from Spata7 mutant retinas have severely shortened and disorganized outer segments (Figure 3g ). As expected, contralateral treated retinas show normally organized outer segments and densely stacked disc membranes (Figure 3f ), although the length of the OS is still shorter than that of age-matched wild-type retinas (Figure 3e ). In addition, treated retinas show better inner segment morphology ( Figure 3f ) compared with contralateral controls (Figure 3g ). These results suggest that AAV8-Spata7 treatment is able to substantially improve the ultrastructure of Spata7 mutant photoreceptors.
We also found that AAV8-Spata7 treatment can maintain structural measures for at least 1 year. We examined AAV8-Spata7-mediated therapeutic effects at 50 weeks post injection. As shown in Figure 4 , treated Spata7 mutant retinas clearly exhibit greater thickness and improved morphology of outer segments, inner segments, and the ONL (Figures 4a and c) compared with the contralateral untreated retinas (Figures 4b and e ). Compared with wild-type controls (Figure 4d ), treated retinas still contain about 50% of the normal number of photoreceptor cells (Figure 4c ) while untreated contralateral retinas contain only one layer of photoreceptor cells (Figure 4e ). Using adjacent sections of the samples shown in Figures 4a and b , we checked AAV8-Spata7 and rhodopsin expression as well as cone photoreceptor cell morphology and function. Treated retinas show AAV8-Spata7 expression at both the temporal and nasal sides of the optic nerve head, which is accompanied by preserved ONL and correct rhodopsin localization (Figure 4f ) as well as by good cone sheath morphology ( Figure 4h ) compared with untreated retinas (Figures 4g and i) . Improvement of cone photoreceptor function was also reflected by the cone-mediated ERG b-wave analysis. We find that the b-wave amplitudes of treated retinas are about 40% of wild-type, whereas untreated retinas are only 16% of wild-type ( Supplementary Figure S3a ). At this time point, treated retinas also show improvement of photoreceptor outer segment ultrastructure (Figure 4k ). Compared with wild-type, although the density of treated outer segments is lower, their length is similar (Figures 4j and k) . In contrast, untreated outer segments are severely shortened and disorganized (Figure 4l ).
AAV8-Spata7 mediated therapeutic effects are also achieved in P28-and P56-treated Spata7 mutant mice We examined P28-and P56-treated Spata7 mutant mice at 32 and 52 weeks of age to evaluate whether AAV8-Spata7 could be used Although the density of outer segments is lower than that of wild-type animals, the length is similar. In contrast, the outer segments of untreated eyes are completely disorganized (l). RPE, retinal pigment epithelium; OS, outer segment; IS, inner segment; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer.
to treat adult mice as Spata7 mutant mice have a wide time window of disease progression. At two selected time points, we observed significantly improved scotopic ERG a-and b-waves in both treatments (Figures 5a-d) . In addition, we measured photopic cone-mediated ERG b-waves at 52 weeks of age and also observed significant functional improvement (Supplementary Figure S3b and c) . The improved ERGs associate with the alleviation of photoreceptor degeneration (Figures 5e and g) and rhodopsin mislocalization (marked by white arrowhead, Figures 5f and h) , as well as preserved cone cells, as assessed by PNA staining of cone sheaths, in treated retina (Figure 5e ). Rhodopsin staining is also consistent with improvement of OS structure (Figure 5f ) in comparison with untreated retinas (Figure  5h ), indicating that treatment in adults (P28 and P56) can also be effective.
AAV8-Spata7 mediated gene therapy has limited but detectable efficacy at 86 weeks of age We kept P15-, P28-, and P56-treated mice that repeatedly showed improved ERGs to 86 weeks of age to further evaluate the longterm therapeutic effects of AAV8-Spata7 therapy. At this age, except for one P15-treated eye, which displayed a very weak ERG response (data not shown), ERG signals were absent, similar to their contralateral untreated eyes. Indeed, untreated retinas showed either complete photoreceptor loss (Figure 6a ) or only sporadic photoreceptors (data not shown) and no SPATA7 or rhodopsin immunoreactivity (Figures 6a and b ). P15-, P28-and P56-treated retinas all showed rhodopsin expression (red) and photoreceptor cell nuclei (marked by white arrowhead) (Figures 6c, g and i) , as well as AAV8-Spata7 expression ( Figures  6d, h and j) . However, we found that AAV8-Spata7 expression in all retinas examined (n = 7) is very weak and restricted to a small region (Figures 6d, h and j) compared with AAV8-Spata7 expression at earlier time points (Figure 3b ; Supplementary  Figure S1a and d) . This result likely explains why treated eyes at the latest time point showed little or no response to light even though treated photoreceptor cells were observed (Figures 6c, f , g and i) compared with contralateral untreated controls (Figure 6e) . In contrast, we found that AAV8-Spata7 injected wild-type retinas still shows strong AAV8-Spata7 expression in a large area of photoreceptors as observed at earlier time points (Supplementary Figure S2c) , excluding the possibility that AAV8-Spata7 expression cannot last for more than one year and thus lead to photoreceptor loss. We also note that a limited number of photoreceptor cells survive in all treated retinas (Figures 6c, g and i) , accompanied by small regions of AAV8-Spata7 expression. These results are consistent with previously reported results that the majority of photoreceptors treated in the degeneration stage are destined for progressive loss. 23 
DISCUSSION
Spata7 null mutant mice show progressive degeneration of photoreceptor cells and a dramatic reduction in photoresponses beginning at P15. 10 We have demonstrated that both photoreceptor degeneration and retinal function impairment can be ameliorated by AAV8-Spata7-mediated gene replacement therapy. All treated Spata7 mutant eyes, receiving AAV8-Spata7 at P15, P28 and P56, show higher scotopic ERG a-and b-wave amplitudes in comparison with contralateral control eyes and this visual function improvement is stable to at least one year of age. Further histological analyses reveal that rhodopsin mislocalization, a potential trigger for photoreceptor degeneration, is significantly alleviated by AAV8-Spata7 expression. As expected, the reduction of rhodopsin mislocalization is accompanied by a significantly thicker ONL, indicating improved photoreceptor cell survival. Moreover, the ultrastructure of photoreceptors is improved in Spata7 mutant mice after treatment with AAV8-Spata7. Nevertheless, ERGs in treated retinas were found to decrease with time. This is likely to result in part from the normal aging process as a similar decline is observed in ERG measurements of wild-type animals ( Supplementary Figure S2a and b) . However, photoreceptor cells that do not receive AAV8-Spata7 transduction in treated retinas still undergo the same rate of degeneration observed in untreated Spata7 mutant retinas. It might be possible to improve treatment by providing multiple injections and gain a higher percentage of photoreceptor cells with AAV8-Spata7 transduction. Taken together, these data show substantial improvement of Spata7 mutant retinal phenotype and that this treatment is effective over a wide treatment time window.
Although AAV8-Spata7 mediated therapeutic effects last for at least one year, we observe that most treated photoreceptor cells are not able to survive for substantially longer time periods, consistent with results of others. 23 At 86 weeks of age, treated retinas with significantly increased ERGs at earlier time points show only a small number of cells with weak AAV8-Spata7 expression and a correspondingly limited rescue of photoreceptors. There are at least three obvious reasons why photoreceptors do not survive well past one year. First, our treatment at P15 occurs after the degenerative phase has already begun. In a dog model for RPE65, treatment prior to the degenerative phase indeed improves photoreceptor survival. 23 However, we are unable to directly test this first hypothesis because treatments in our Spata7 model prior to P15 lead to retinal detachment (data not shown). Second, although it is possible that the FLAG tag on SPATA7 interferes with normal protein function, we can exclude this second hypothesis because we have also generated transgenic mice with FLAG-tagged Spata7 genomic construct that completely rescues all known Spata7 null mutant phenotypes. 10 Finally, the timing, pattern, and level of AAV8-Spata7 expression are not the same as endogenous SPATA7 and this may lead to failure of complete long-term rescue. Unlike Pax6, 24 it is unlikely that mice are sensitive to the dose of Spata7. In particular, Spata7 is fully recessive and heterozygotes present no readily detectable phenotype. 10 In addition, overexpression of AAV8-Spata7 in wild-type animals does not lead to photoreceptor death (Supplementary Figure S2) . Therefore, it is most likely that the failure of photoreceptor survival is due to either incorrect timing or pattern of SPATA7 expression, or both.
Our results provide another example of successful gene replacement therapy in a mouse model of rod and cone photoreceptor degeneration by using the combination of AAV8 (Y773F) and the hGRK1 promoter. In our treatments, we observe large areas of high AAV8-Spata7 expression specifically in photoreceptor cells and this is sufficient to achieve significant functional improvement of both rod and cone photoreceptors. These data and results of others suggest that the combination of AAV8(Y773F) and hGRK1 works well for the treatment of Spata7, Gcdko, RPGRIP, and Aipl1 mutant mice, 17, 19, 25 and it is likely to also be effective for treating retinopathies caused by other photoreceptor-specific gene defects.
Successful therapeutic effects by AAV8-Spata7 expression further suggest that Spata7 functions in photoreceptors. In humans, clinical data suggest that loss of SPATA7 function causes LCA and RP; specifically, rod and cone-driven ERGs are undetectable in patients with strong loss-of-function SPATA7 mutations. 3, 8, 9 This demonstrates that SPATA7 mutation causes the dysfunction of photoreceptors and there may be a similar function between SPATA7 and Spata7. In SPATA7 patients, rod driven ERGs were found to decrease with age. 8 Moreover, high-resolution optical coherence tomography scans showed preservation of foveal architecture early in the course of the disease, indicating a window of opportunity for therapy. 8 Therefore, the therapeutic efficacy by AAV8-Spata7 expression in mice suggests the feasibility of treating SPATA7 patients by an analogous AAV-mediated gene replacement therapy, although it will be necessary to find a way to achieve longer-term or permanent rescue as in our Spata7 transgenic mice.
MATERIALS AND METHODS
Production of AAV8(Y733F) vectors
Full-length Spata7 cDNA was amplified from mouse retinal cDNA using primers that were designed according to the known Spata7 cDNA sequence (Transcript ID in Ensembl database: ENSMUST00000048402). In order to accurately examine future transgene expression, a 3 × FLAG epitope tag (Sigma, St Louis, MO, USA) was added to the N terminus of Spata7 and then cloned into a pTR-hGRK1 AAV vector. Using the AAV8 capsid protein with a Y733F surface-exposed tyrosine residue mutation, an AAV8(Y733F)-hGRK1-3 × FLAG-Spata7 viral vector was produced as previously described 17 and the viral titer was 3.18 × 10 13 vg μl − 1 . Serving as controls in this study, AAV8(Y733F)-hGRK1-GFP viral vector was also produced and titered at 2.31 × 10 13 vg μl − 1 .
Animals
Spata7 knockout mice were generated as previously described 10 and maintained on C57BL/6 genetic background. All mice in this study were maintained under light cycles of 12-h light and 12-h dark. All animal operations were approved by the Institutional Animal Care and Use Committee at Baylor College of Medicine.
Subretinal injection
The subretinal injections were performed as described in Simons et al. 26 Briefly, mice were anesthetized and then a very shallow puncture was made through the sclera immediately in the dorsal hemisphere using a beveled 30-gauge needle. Through this puncture, a 35-gauge blunt needle was introduced into the vitreous cavity and advanced ventrally until the tip of the needle had penetrated the retina. Viral suspension was injected into the subretinal space using an UltraMicroPump II and Micro4 Controller (World Precision Instruments, Sarasota, FL, USA). In this study, P15 mice were treated in the right eye using AAV8(Y733F)-Spata7, leaving the contralateral left eye to be uninjected or injected by AAV8(Y733F)-GFP as an internal control (therefore, any left eye is described as 'contralateral untreated' throughout this text). The injection concentrations of AAV8 (Y733F)-Spata7 and AAV8(Y733F)-GFP were adjusted to 1 × 10 9 , 1 × 10 8 and 1 × 10 7 vg μl − 1 to generate three groups of treatments and 1 microliter was injected for each eye. To evaluate whether AAV8-Spata7 could be used to treat adult mice, P28 and P56 Spata7 mutant mice were treated in the right eye by 1 μl of 1×10 9 vg μl − 1 of AAV8(Y733F)-Spata7, leaving the contralateral left eye uninjected. For each treatment group with different injection concentration or different age, 6 or more mice were collected, including males and females, so that we can statistically (n43) evaluate AAV8-Spata7 mediated therapeutic effects and these individuals were collected from one or two litters from the same parents in order to avoid differences in genetic background.
Electroretinographic analysis
Treated mice were dark-adapted overnight and then anesthetized by a single intraperitoneal injection of 22 mg kg − 1 ketamine, 4.4 mg kg − 1 xylazine and 0.37 mg kg − 1 acepromazine. Both pupils were dilated with a drop of tropicamide (1.0%) and phenylephrine (2.5%) and then corneas were anesthetized with a drop of proparacaine (1.0%). After 1 min, excess fluid was removed and a drop of hypromellose (2%) was placed on each cornea to keep it moistened and provide a good contact between the cornea and the ERG electrode (N1530NNC). All tests were performed under a dim red light and a feedback-controlled heating pad was used to keep treated mice at a constant body temperature of 37.6°C. Six flash intensities (−34, − 24, − 14, − 4, 0 and 10 dB) were used to record scotopic ERG a-and b-waves. In this study, scotopic ERG recordings were performed at 8, 16, 24 and 52 weeks of age for P15-treated mice and at 32 and 52 weeks of age for P28-and P56-treated mice, on the UTAS Visual Diagnostic System and EMWIN software (LKC Technologies, Gaithersburg, MD, USA). In addition, photopic ERGs were continually recorded after scotopic ERG recordings for ERG tests at 52 weeks of age. According to the literature, 17 mice were lightadapted to a 30 cd*s/m 2 white background for 2 min after scotopic ERG recordings and then photopic ERGs were recorded with flash intensities of 0, 10 and 25 dB.
Immunoblotting and immunohistochemical analysis
